达帕格利弗洛辛通过提高β-基酸盐激活的酸合成酶来减轻心力衰竭与保存的喷射部分重塑和功能障碍
Xinxin Zhang1, Ning Wang1, Peng Fu1
1Department of Cardiology, Institute of Cardiovascular Diseases.
Journal of cardiovascular pharmacology
|August 29, 2023
概括
-葡萄糖共运输体亚型抑制剂 (SGLT2i) 在用保存的喷射分数 (HFpEF) 治疗心力衰竭方面表现有前途. 达帕格利弗洛辛通过向HFpEF模型和患者的代谢途径,改善了心脏功能并减少了不良重塑.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭是一种普遍存在的疾病,死亡率高.
- 目前的指导方针建议SGLT2抑制剂 (SGLT2i) 用于HFpEF,但它们的确切机制尚不清楚.
- 了解SGLT2i的作用对于HFpEF病理生理学和治疗开发至关重要.
研究的目的:
- 在临床前的HFpEF模型中研究SGLT2抑制剂,特别是达帕格利弗洛辛 (DAPA) 的治疗机制.
- 阐明DAPA如何影响HFpEF中的心脏重塑,功能障碍和代谢途径.
- 为了将临床前发现与接受DAPA治疗的HFpEF患者观察到的变化相关联.
主要方法:
- 使用高脂肪饮食和L-NAME管理 (2-Hit模型) 建立了一个HFpEF大鼠模型.
- 用达帕格利弗洛辛 (DAPA) 来评估其对心脏结构,功能和分子标记物的影响.
- 进行了体内和患者血液样本中的代谢分析,包括β-基黄油酸 (β-OHB),酸合成酶,乙-CoA,ATP和线粒体氧化酸化.
主要成果:
- 在HFpEF模型中,DAPA治疗显著减轻心肌细胞缩,亡,炎症,氧化应激和纤维化.
- 在晚期HFpEF中,DAPA改善了透析和收缩心脏功能.
- 在机械上,DAPA通过增加β-OHB,激活酸盐合成酶,减少乙-CoA,调节ATP产生和增强线粒体氧化酸化来使能量代谢正常化.
结论:
- 达帕格利弗洛辛为例的SGLT2抑制剂在预防和治疗心脏重塑和HFpEF功能障碍方面具有显著的好处.
- DAPA通过改善心脏代谢失调,特别是通过调节脂肪酸代谢和线粒体功能来发挥其保护作用.
- 临床数据支持DAPA在HFpEF患者中观察到的代谢益处,突出其治疗潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K